A Phase 4 interventional study of ENDOMETRIAL BIOPSY in Hyperprolactinemia and Endometriosis, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA. Completed at 1 site in Spain. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2009-01-12.
Sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA · Phase 4, Interventional, and Health services research
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.
39 studies on the registry are indexed under Hyperprolactinemia; 4 are open to participants now.
This study's planned enrollment of 5 is below the median of 60 across 20 interventional studies indexed under Hyperprolactinemia.
Browse Hyperprolactinemia studies →Instituto Valenciano de Infertilidad, IVI VALENCIA is the lead sponsor of 72 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
observation of three month treatment with Quinagolida in endometriosis patients
Time frame: onset and three months after onset
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Valenciano de Infertilidad, IVI VALENCIA